SC issues notice on PIL seeking action against doctors who do not prescribe generic medicines

New Delhi : The Supreme Court on Friday issued notice on a PIL seeking disciplinary actions against doctors who fail to prescribe generic medicines.

A bench comprising Chief Justice of India D.Y. Chandrachud, Justices J.B. Pardiwala and Manoj Misra sought response from the Centre, all state governments, Ethics and Medical Registration Board (erstwhile Medical Council of India) and others in the matter.

Advocate K.C. Jain, the petitioner, apprised the bench that regulations emphasizing the importance of prescribing generic medicines, which were notified back in 2002, remain largely unimplemented in practice.

He said that the Indian Medical Council (Professional Conduct, Etiquette, and Ethics) Regulations, 2002, which highlight the significance of prescribing drugs by their generic names, exist solely within legal frameworks.

The plea said that affordability of medicines is a vital factor that contributes to effective healthcare delivery and the realization of the ‘right to health’.

“Generic drugs, which have the same active ingredients as their branded counterparts but are not marketed under a specific brand name, are often significantly cheaper. The prices of generic medicines (off-patented) can be 50 per cent to 90 per cent lower than those of branded medicines,” stated the petition.

It sought directions to the National Pharmaceuticals Pricing Authority to fix the Maximum Retail Price (MRP) of Non Scheduled formulations and off-patented generic medicines.

“By prescribing generic drugs, healthcare professionals can help alleviate the financial burden on patients and facilitate their access to vital medications,” the plea said.

Related Posts

Gene Therapy for Cholesterol: Initial Test Results Cheer

Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Gene Therapy for Cholesterol: Initial Test Results Cheer

Gene Therapy for Cholesterol: Initial Test Results Cheer

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

US Biotech Regeneron to launch Global Capability Centre in Hyderabad

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

STF busts fake meds racket spread across 6 states

STF busts fake meds racket spread across 6 states